EAM
BPMC

Eagle Asset Management’s Blueprint Medicines BPMC Stock Holding History

Eagle Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$15.6M Sell
154,652
-34,215
-18% -$3.4M 0.08% 221
2024
Q2 		$20.6M Sell
188,867
-32,384
-15% -$3.24M 0.11% 175
2024
Q1 		$21.3M Sell
221,251
-10,145
-4% -$870K 0.11% 183
2023
Q4 		$21.3M Buy
231,396
+22,279
+11% +$1.44M 0.11% 184
2023
Q3 		$10.5M Buy
209,117
+4,732
+2% +$253K 0.06% 251
2023
Q2 		$12.9M Buy
204,385
+39,749
+24% +$2.16M 0.07% 230
2023
Q1 		$7.41M Sell
164,636
-14,800
-8% -$667K 0.04% 289
2022
Q4 		$7.77M Buy
179,436
+4,154
+2% +$199K 0.05% 269
2022
Q3 		$11.5M Sell
175,282
-13,934
-7% -$895K 0.08% 218
2022
Q2 		$9.56M Sell
189,216
-167,813
-47% -$9.83M 0.06% 248
2022
Q1 		$22.8M Sell
357,029
-27,598
-7% -$1.98M 0.12% 186
2021
Q4 		$42.1M Sell
384,627
-12,602
-3% -$1.32M 0.18% 159
2021
Q3 		$40.8M Sell
397,229
-55,656
-12% -$5.18M 0.18% 169
2021
Q2 		$39.8M Sell
452,885
-11,729
-3% -$1.07M 0.17% 177
2021
Q1 		$45.5M Sell
464,614
-372
-0.1% -$37.1K 0.2% 164
2020
Q4 		$52.1M Sell
464,986
-59,754
-11% -$6.3M 0.29% 118
2020
Q3 		$48M Sell
524,740
-45,757
-8% -$3.52M 0.25% 149
2020
Q2 		$43.7M Sell
570,497
-29,607
-5% -$2M 0.25% 146
2020
Q1 		$35.1M Sell
600,104
-164,476
-22% -$10.6M 0.22% 161
2019
Q4 		$61.3M Sell
764,580
-3,748
-0.5% -$281K 0.29% 135
2019
Q3 		$56.4M Buy
768,328
+6,150
+0.8% +$532K 0.29% 139
2019
Q2 		$71.9M Sell
762,178
-1,730
-0.2% -$143K 0.37% 103
2019
Q1 		$61.1M Buy
763,908
+2,639
+0.3% +$195K 0.33% 126
2018
Q4 		$41M Sell
761,269
-17,414
-2% -$1.06M 0.26% 158
2018
Q3 		$60.8M Buy
778,683
+643,841
+477% +$44.7M 0.29% 140
2018
Q2 		$8.56M Buy
+134,842
New +$10.7M 0.05% 347

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eagle Asset Management's BPMC Position: Q3 2024 in Review

Eagle Asset Management reduced its Blueprint Medicines (BPMC) stake by 18% in Q3 2024, selling an estimated $3.4M and leaving 154,652 shares worth $15.6M. The position accounts for 0.08% of the portfolio, ranked #221.

Eagle Asset Management first reported a position in BPMC in Q2 2018 and has held it in 26 quarters since. The position peaked at $71.9M in Q2 2019. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • Eagle Asset Management held 154,652 shares of Blueprint Medicines worth $15.6M as of Q3 2024.
  • Eagle Asset Management sold 34,215 Blueprint Medicines shares in Q3 2024, an estimated $3.4M.
  • Blueprint Medicines made up 0.08% of Eagle Asset Management's portfolio in Q3 2024, its #221 holding.
  • Eagle Asset Management first reported a position in Blueprint Medicines in Q2 2018 and has held it in 26 quarters since.
  • Eagle Asset Management's Blueprint Medicines position peaked at $71.9M in Q2 2019.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.